Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
Circulation · 27.01.2026 · 153 (4) · 214-225
DOI: 10.1161/circulationaha.125.077304 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 27.01.2026. Verfasst von Marianna Fontana und 14 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, University College London (Royal Free Campus), United Kingdom (M.F.). Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cardiomyopathies, Amyloid Neuropathies, Familial, Prealbumin. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.
Abstract (Originalsprache)
BACKGROUND: Transthyretin amyloidosis with cardiomyopathy is a progressive disease caused by the deposition of transthyretin (TTR) as amyloid in the myocardium. Current therapies may slow disease progression but do not clear existing deposits. Coramitug is a humanized monoclonal antibody that targets misfolded transthyretin, designed to promote clearance of transthyretin amyloid through antibody-mediated phagocytosis. METHODS: This phase 2, double-blind, placebo-controlled trial randomized participants with transthyretin amyloidosis with cardiomyopathy to receive infusions every 4 weeks of either coramitug at 2 dosages (10 mg/kg or 60 mg/kg) or placebo in a 1:1:1 ratio for 52 weeks. The primary end points were the change from baseline to week 52 in the 6-minute walk test and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels. Safety was assessed for up to 64 weeks by assessing treatment-emergent adverse events, all-cause mortality, and number of cardiovascular events (comprising hospitalization caused by cardiovascular events or urgent heart failure visits). RESULTS: In total, 104 participants (median age, 77 years; 93% men; 84% New York Heart Association class II; 13% with variant transthyretin amyloidosis with cardiomyopathy) were randomized and dosed: 34 to 10 mg/kg of coramitug, 35 to 60 mg/kg of coramitug, and 35 to placebo. Median NT-proBNP was 1985 pg/mL (interquartile range, 1224, 3406). In total, 90% of participants were receiving disease-modifying therapy; 84% were treated with tafamidis and 7 (6.7%) with transthyretin silencers (patisiran, n=4; vutrisiran, n=3). From baseline to week 52, 60 mg/kg of coramitug significantly reduced NT-proBNP levels compared with placebo (–48% [95% CI, –65% to –22%]; P =0.0017). The change in 6-minute walk test from baseline to week 52 was not statistically different from placebo with either dose. Coramitug (60 mg/kg) was associated with improved functional echocardiographic parameters and was well tolerated. CONCLUSIONS: This phase 2 trial showed that coramitug, an antibody targeting misfolded transthyretin in transthyretin amyloidosis with cardiomyopathy, was well tolerated and, at a dose of 60 mg/kg, resulted in a statistically significant reduction in NT-proBNP, a validated marker of disease progression, with no statistically significant effect on 6-minute walk test within 52 weeks. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05442047.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Amyloidosis Centre, University College London (Royal Free Campus), United Kingdom (M.F.).
- Department of Cardiology, Hospital Universitario Puerta de Hierro de Majadahonda, Health Research Institute of the Puerta de Hierro Majadahonda-Segovia de Arana, Centro de Investigación Biomédica en Red Enfermedades Car…
- Department of Cardiology, Mayo Clinic, Rochester, MN (M.G.).
- Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (S.J.S.).
- Novo Nordisk A/S, Søborg, Denmark (M.D.M.E, G.K.H., M.R.).
- Department of Cardiology, Angiology, and Pneumology, Medical University of Heidelberg, Germany (A.V.K.).
ORCID-Profile: Marianna Fontana, Pablo García-Pavía, Martha Grogan, Sanjiv J Shah, Michelle Z Lim-Watson, Brian Malling, Soumitra Kar, Nitasha Sarswat, Kenichi Tsujita, Kevin M Alexander, Mathew S Maurer
Förderung
- Novo Nordisk A/S
Zitieren
APA
Fontana, M., García-Pavía, P., Grogan, M., Shah, S. J., Engelmann, M. D. M., Hovingh, G. K., Kristen, A. V., Lim-Watson, M. Z., Malling, B., Kar, S., Revanna, M., Sarswat, N., Tsujita, K., Alexander, K. M., & Maurer, M. S. (2026). Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Circulation, 153(4), 214-225. https://doi.org/10.1161/circulationaha.125.077304
Vancouver
Fontana M, García-Pavía P, Grogan M, Shah SJ, Engelmann MDM, Hovingh GK, et al. Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Circulation. 2026;153(4):214-225. doi:10.1161/circulationaha.125.077304
BibTeX
@article{Fontana2026,
author = {Fontana, Marianna and García-Pavía, Pablo and Grogan, Martha and Shah, Sanjiv J and Engelmann, Mads D M and Hovingh, G Kees and Kristen, Arnt V and Lim-Watson, Michelle Z and Malling, Brian and Kar, Soumitra and Revanna, Manjunatha and Sarswat, Nitasha and Tsujita, Kenichi and Alexander, Kevin M and Maurer, Mathew S},
title = {Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial},
journal = {Circulation},
year = {2026},
volume = {153},
number = {4},
pages = {214--225},
doi = {10.1161/circulationaha.125.077304}
}
EUVIMED